Evaluation on the usefulness of protocol for pharmacists facilitating laboratory monitoring to ensure safety in lung cancer patients receiving immune checkpoint inhibitors

Evaluation on the usefulness of protocol for pharmacists facilitating laboratory monitoring to ensure safety in lung cancer patients receiving immune checkpoint inhibitors - Usefulness of pharmacists facilitating laboratory monitoring in patients receiving immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031991

Enrollment

Registered

2018-03-29

Start date

2018-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult lung cancer patients receiving immune checkpoint inhibitors between 2018 April and 2019 March

Exclusion criteria

Exclusion criteria: 1. Patients previously received immune checkpoint inhibitors. 2. Patients who expected to be difficult to assess irAEs due to dementia or psychiatric diseases. 3. Patients who have severe comorbidities.

Design outcomes

Primary

Measure	Time frame
Adherence to laboratory monitoring which was stated in the protocol	—

Secondary

Measure	Time frame
-Immune-related adverse events in early phase -Number of laboratory order entries by pharmacist -Required time for laboratory order entries by pharmacist -Problems associated with the protocol for pharmacists facilitating laboratory monitoring	—

Countries

Japan

Contacts

Public ContactHiroaki Ikesue

Kobe City Medical Center General Hospital Department of Pharmacy

ikesue@kcho.jp078-302-4321

Outcome results